10/30/2026
A meaningful step forward for peptide access.
HHS has announced an interim enforcement discretion policy involving six peptides:
BPC-157 • KPV • TB-500 • MOTS-c • Semax • Epitalon
Why does this matter?
The policy creates a pathway focused on greater oversight around sourcing, quality, labeling, reporting, and patient-specific compounding while the FDA continues its rulemaking process around the Section 503A Bulks List.
This is not FDA approval, and the regulatory process is still evolving.
But for a space that has long been complicated by gray-market products and inconsistent sourcing, movement toward a more controlled, physician-guided pathway is significant.
We’ll be following this closely as the regulatory landscape continues to develop.
Compounded medications are not FDA-approved. This content is for educational purposes only.